BBig Pharma’s China deal spree grows with latest tie-up worth up to $7.8 billion
Western biopharma companies are increasingly turning to China to source innovation, as pharma's dreaded "patent cliff" draws closer.
Western biopharma companies are increasingly turning to China to source innovation, as pharma's dreaded "patent cliff" draws closer.
Consumer News and Business Channel
This report is indexed by BAGANBAZAR GRAPH with its original publisher named and linked for readers.
Read at original outlet ↗